Miraxion FDA Approval Status
FDA Approved: No
Brand name: Miraxion
Generic name: eicosapentaenoic acid (EPA)
Company: Amarin Corporation plc
Treatment for: Huntington's Disease
Miraxion (eicosapentaenoic acid) is a phospholipid-based TLA2 inhibitor in development for the treatment of Huntington’s disease.
Development timeline for Miraxion
|Nov 19, 2007||Amarin Announces Completion of Comprehensive Data Analysis From Phase III Huntington's Disease Program|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.